Opiant Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Opiant Pharmaceuticals han disminuido a una tasa media anual de -22.2%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 1.7% anualmente. Los ingresos han ido creciendo a una tasa media de 10.3% al año.

Información clave

-22.2%

Tasa de crecimiento de los beneficios

-10.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	10.3%
Rentabilidad financiera	-161.4%
Margen neto	-148.1%
Última actualización de beneficios	30 Sep 2022

Actualizaciones de resultados anteriores recientes

Recent updates

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Aug 13

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Aug 08

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 05

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Mar 21

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 19

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Nov 17

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Sep 19

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Aug 07

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

Jun 09

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Mar 06

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Mar 05

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Jan 27

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Dec 14

Opiant Pharmaceuticals receives $50M in convertible debt financing

Dec 10

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Opiant Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:OPNT Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 22	22	-33	24	0
30 Jun 22	39	-20	23	0
31 Mar 22	46	-6	20	0
31 Dec 21	48	3	17	0
30 Sep 21	44	2	16	0
30 Jun 21	37	-1	16	0
31 Mar 21	32	-3	16	0
31 Dec 20	30	-2	16	0
30 Sep 20	27	0	15	0
30 Jun 20	39	10	15	0
31 Mar 20	39	12	13	0
31 Dec 19	41	12	13	0
30 Sep 19	38	1	12	0
30 Jun 19	21	-11	12	0
31 Mar 19	18	-14	12	0
31 Dec 18	14	-21	11	0
30 Sep 18	34	-2	18	0
30 Jun 18	29	-5	17	0
31 Mar 18	30	-3	16	0
31 Dec 17	28	3	15	0
31 Oct 17	17	2	11	4
31 Jul 17	18	7	8	0
30 Apr 17	15	6	7	2
31 Jan 17	18	9	5	3
31 Oct 16	11	3	5	3
31 Jul 16	10	-8	15	3
30 Apr 16	10	-8	15	4

Ingresos de calidad: OPNT actualmente no es rentable.

Margen de beneficios creciente: OPNT actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: OPNT no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 22.2% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de OPNT en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: OPNT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (-6.8%).

Rentabilidad financiera

Alta ROE: OPNT tiene una rentabilidad financiera negativa (-161.39%), ya que actualmente no es rentable.

Opiant Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Opiant Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Opiant Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Opiant Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose

President recently sold US$102k worth of stock

Consensus revenue estimates increase by 15%

Price target decreased to US$21.50

Opiant Pharmaceuticals, Inc. Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose

Consensus revenue estimates fall by 45%

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Insufficient new directors

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Opiant Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Opiant Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering Opnt004 for the Treatment of Cannabinoid Hyperemesis Syndrome

Consensus revenue estimates fall by 13%

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Opiant Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Opiant Pharmaceuticals, Inc. announced that it expects to receive $2.1 million in funding from AptarGroup, Inc., Valois SAS

Independent Director recently sold US$275k worth of stock

Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

Independent Chairman recently bought US$368k worth of stock

Consensus EPS estimates fall by 47%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Opiant Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

Opiant Pharmaceuticals, Inc. Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone

Insufficient new directors

Opiant Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Investor sentiment improved over the past week

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorated over the past week

President recently sold US$52k worth of stock

Opiant Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Trial of Opnt002

Investor sentiment deteriorated over the past week

Insufficient new directors

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Investor sentiment deteriorated over the past week

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Third quarter 2021 earnings released: EPS US$0.77 (vs US$0.17 in 3Q 2020)

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Independent Chairman recently bought US$174k worth of stock

Independent Director exercised options and sold US$1.6m worth of stock

Second quarter 2021 earnings released: EPS US$0.39 (vs US$0.051 loss in 2Q 2020)

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Consensus revenue estimates increase to US$37.0m

Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from Russell 3000E Value Index

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.40 loss in 1Q 2020)

Opiant Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2021

Independent Director exercised options to buy US$101k worth of stock.

Analysts update estimates

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Full year 2020 earnings released: US$0.44 loss per share (vs US$2.89 profit in FY 2019)

Revenue and earnings beat expectations

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Opiant Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 04, 2021

Independent Director exercised options to buy US$97k worth of stock.

Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

New 90-day high: US$12.96

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Opiant Pharmaceuticals, Inc. Appoints Craig A. Collard to the Compensation Committee of the Board

New 90-day high: US$9.29

Opiant Pharmaceuticals Announces Additional $3.5 Million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Opiant Pharmaceuticals receives $50M in convertible debt financing

Opiant Pharmaceuticals Announces Appointment of Craig A. Collard as Chairman to Its Board of Directors

Analysts increase EPS estimates to -US$0.20

Desglose de ingresos y gastos
Beta